Diletta Fontana

Recurrent ETNK1 mutations in atypical chronic myeloid leukemia

Carlo Gambacorti‐Passerini, Carla Donadoni, Andrea Parmiani et al. · Blood · 2014 · 131 citations · Full text

Medicine, Genetics, Oncology +12

Activity of second‐generation ALK inhibitors against crizotinib‐resistant mutants in an NPM‐ALK model compared to EML4‐ALK

Diletta Fontana, Monica Ceccon, Carlo Gambacorti‐Passerini et al. · Cancer Medicine · 2015 · 88 citations · Full text

Medicine, Oncology, Pharmacology +16

Large-scale analysis of SARS-CoV-2 synonymous mutations reveals the adaptation to the human codon usage during the virus evolution

Daniele Ramazzotti, Fabrizio Angaroni, Davide Maspero et al. · Virus Evolution · 2022 · 65 citations · Full text

Life Sciences, Evolutionary Biology, Infectious Diseases +17

Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK–Positive Anaplastic Large Cell Lymphoma

Monica Ceccon, Luca Mologni, Giovanni De Giudici et al. · Molecular Cancer Research · 2014 · 56 citations · Full text

Medicine, Oncology, Pharmacology +16

ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine

Diletta Fontana, Mario Mauri, Rossella Renso et al. · Nature Communications · 2020 · 49 citations · Full text

Life Sciences, Molecular Biology, Oncology +15